XNYS · Medical Instruments & Supplies
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$65.04-0.21%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
44/100
Weak
Score components
TickerWhale View
Alcon scores 44 out of 100 overall, which we rate weak. Risk is its strongest area and Technical its weakest.
What helps
- Quality & growth
- Risk
- Sentiment Signal
What to watch
- Technical
- Valuation
Quality & growth
30%61Positive
- Revenue growth 8.3%
- EPS growth -39.1%
Valuation
25%27Weak
- P/E 49.4
- EV/Sales 3.3
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
#341 by market cap in our coverage · ~25,942 employees · Listed 2019-04-09 · www.alcon.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#111 / 139sector rank by TickerWhale Score
TickerWhale Score 44 vs sector average 55.1 (-11.1)
Revenue growth (industry)Top 64%
Gross margin (industry)Top 40%
Return on equity (industry)Top 67%
P/E (industry)Pricier than 58%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
26/100Weak vs universe
Ranks 26th of 100 covered names on our technical composite — the composite itself scores 34/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 5 sell · 1 neutral of 8 votes
TickerWhale rates ALC's technical setup weak — 26th percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
0 / 9constructive
- vs 200-day-12.1%
- vs 50-day-7.4%
Momentum
Mixed
- RSI (14)31 · neutral
- Stochasticbuy
- CCIsell
- Williams %Rbuy
Trend
Weak
- ADX (14) trend strength23· trending
- MACD (12,26,9)sell(histogram -0.670)
How the classic verdict is reached
Moving averages (9) agree on sell — 0 buy vs 9 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 4 sell · 1 neutral.
Result — 2 buy vs 5 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)49.4
- P/S (TTM)2.9
- P/B1.5
- EV/EBITDA13.0
- EV/Sales3.3
- PEG—
Profitability & returns
- Gross margin56.9%
- Net margin5.9%
- ROE2.9%
- Debt/Equity0.25
Growth
- Revenue growth (YoY)8.3%
- EPS growth (YoY)-39.1%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $31.8B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $10.4B | $9.9B | $9.5B |
| Gross profit | $5.7B | $5.5B | $5.2B |
| Operating income | $1.2B | $1.3B | $959M |
| Net income | $980M | $1.0B | $974M |
| EPS (diluted) | $1.98 | $2.05 | $1.96 |
| Free cash flow | $1.7B | $1.6B | $730M |
| Cash | $1.6B | $1.8B | $1.1B |
| Total debt | $5.2B | $5.1B | $5.1B |
| Equity | $22.0B | $21.6B | $20.6B |
| Net debt | $3.6B | $3.3B | $4.1B |
| Debt / equity | 0.24 | 0.24 | 0.25 |
| Liabilities / assets | 0.30 | 0.29 | 0.30 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCCurrentAlcon | 44 | 34 | 49.4 | — | 1.5 | 3.3 | $65.04 | -0.21% | +8.3% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.